Artificial Intelligence Combined With 3D-Preformed Chest Wall Defection Reconstruction System in Chest Wall Tumor Surgery
Launched by WU WEIMING · May 11, 2025
Trial Information
Current as of July 01, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is exploring a new approach to surgery for patients with chest wall tumors. The goal is to use advanced technology, specifically artificial intelligence (AI), along with a specially designed 3D system to help doctors remove tumors more effectively and accurately. This method aims to reduce the chances of leaving behind any cancerous tissue during surgery, which is crucial for improving patient outcomes and preventing the tumors from coming back.
To participate in this trial, individuals must be between 18 and 70 years old and have a specific type of chest tumor that hasn’t spread to other parts of the body. They should also be in good overall health, as assessed by their doctor. Participants will undergo surgery using this innovative approach and will be monitored closely for their recovery. It’s important to note that this trial is not yet recruiting participants, but it represents a promising step forward in how chest wall tumors are treated.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. 18-70 years old, male or female not limited
- • 2. Anesthesia ASA score I-II
- • 3. Malignant tumor of soft tissue in the chest
- • 4. Malignant tumors of ribs, rib cartilage, and sternum
- • 5. Tumors with uncertain or unknown properties of ribs, rib cartilage, and sternum
- • 6. Giant benign tumors of ribs, rib cartilage, and sternum
- • 7. The preoperative examination results indicate that the tumor has not undergone distant metastasis
- • 8. Willing to participate in the research and sign the informed consent form
- Exclusion Criteria:
- • 1. Patients with distant metastasis detected during preoperative examination
- • 2. Inoperable tumor
- • 3. During the examination, it was discovered that the patient had another type of malignant tumor present
- • 4. ECOG 4
- • 5. Suffering from active or chronic fungal/bacterial/viral infections
- • 6. History of allergy to anesthesia related drugs
- • 7. Heart and lung dysfunction, liver and kidney dysfunction, inability to tolerate surgery
- • 8. Patients with mental disorders who are unable to cooperate with treatment
About Wu Weiming
Wu Weiming is a dedicated clinical trial sponsor focused on advancing medical research and innovation. With a commitment to improving patient outcomes, the organization collaborates with leading healthcare professionals and institutions to conduct rigorous clinical trials that evaluate the safety and efficacy of new therapies. Wu Weiming emphasizes ethical practices, scientific integrity, and transparency throughout the research process, ensuring compliance with regulatory standards while prioritizing participant welfare. By fostering a collaborative environment, Wu Weiming aims to accelerate the development of groundbreaking treatments that address unmet medical needs.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported